Clinical Study

The effects of estradiol valerate 2.00mg and dienogest 2.00mg combination on activated protein c resistance in healthy postmenopausal women

  • Samet Kafkas
  • Nurdan Yildiz Kalkan
  • Zahit Bolaman
  • Üzeyir Kalkan
  • Ali Riza Odabasi
  • Hasan Yüksel
  • Sabri Batun
  • Ergun Onur

Received Date: 15.09.2006 Accepted Date: 08.11.2006 J Turk Ger Gynecol Assoc 2006;7(4):334-341


It is aimed that, to investigate the effect of estradiol valerate and dienogest combination, which is used as a hormone replacement therapy (HRT) regimen on hemostatic parameters and activated protein C resistance in healthy postmenopausal women.


Fifty seven women received HRT treatment in four month period. The placebo group consisted of 50 women. In the HRT group 10.5% (6/57), and in the placebo group 4% (2/50) were heterozigot of FV Leiden mutation. Hemostatic parameters were investigated in only non-mutation women, to avoid potential effects of FV Leiden mutation on activated protein C.


Although these changes did not reach statistical significance, a comparison of hemostatic parameters for both groups showed that in the study group (receiving 2mgEV/2mgDNG) FV and Protein C levels were increased, and FVIII levels were decreased compared to the placebo group. There were also no significant differences in FVII and free protein S levels. Multiple logistic regression analysis was performed to determine the association of (2mgEV/2mgDNG) treatment with FV, FVII, FVIII, protein C, free protein S and activated protein C sensitivity rate. There was no significant effect of these independent variables on activated protein C sensitivity rate (p>0.05).


Combination of estradiol valerate and dienogest has no effect on activated protein C sensitivity ratios. Hormone replacement therapy does not cause acquired activated protein C resistance (p>0.05).

Keywords: Menopause, Hormone Therapy, Activated Protein C Resistance, Haemostasis